LPCN (Lipocine Corporation) Earnings growth in current year

The success of Lipocine Inc. (LPCN) is based on the efficiency of oral hormone administration and TLANDO sales. Year-over-year EPS changes clearly demonstrate the financial dynamics, where the 18.90 indicator expresses the state of the metric. The Lip'ral platform makes testosterone therapy convenient by eliminating injections. The massive potential of the metabolic disorders market provides the company with opportunities to enter into lucrative licensing agreements with global behemoths.

LPCN: Lipocine Inc. Earnings per share growth in current year 07/04/2022 - 11/15/2026

Financial and market metric breakdowns for Lipocine Inc (LPCN)

- share price and expert price forecast:

Price Lipocine Corp|LPCN - Analyst Consensus Forecast

- business market valuation indicators:

Market Capitalization Lipocine|LPCN - Enterprise Value

- book capitalization data:

Net Assets per Single Share Lipocine|LPCN - Company Book Value|Market-to-Book Ratio lipocine.com|LPCN - Aggregate Company Assets

- debt burden and liquidity indicators:

- earnings and valuation multiples information:

LPCN - Net Profit|Company Profit Forecast Lipocine Inc.|LPCN - Price to Earnings Ratio|Price to Expected Earnings Ratio lipocine.com|LPCN - Price/Earnings to Growth Ratio|Company Value to EBITDA Lipocine|LPCN - Operating profit EBITDA|Net earnings per share for the last 12 months Lipocine|LPCN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months lipocine.com|LPCN - Earnings per share growth in current year|Projected earnings per share growth rate for next year Lipocine Inc.

- revenue and sales proceeds data:

LPCN - Revenue and Sales Volume|Company Expected Sales Volume Lipocine Inc.|LPCN - Market Cap to Revenue|Forward Price to Sales Lipocine|LPCN - Sales Growth YoY (TTM)

Basic company analysis:LPCN - Lipocine Corporation

Lipocine Inc. develops advanced drug delivery systems to combat metabolic disorders. This metric calculates the dynamics of earnings per share relative to the same period last year. By analyzing the annual EPS range, investors assess the monetization efficiency of proprietary technologies. Growth in this metric confirms successful product certification and business scaling. The positive trend justifies the fundamental stability of the assets' market value.

Main competitors